---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-210279"
form_type: "8-K"
ticker: "WW"
cik: "0000105319"
company_name: "WW INTERNATIONAL, INC."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:21:48.067303+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# WW Q1 revenue $168M, net loss $52M; clinical subs up 46%; reaffirms FY guidance; plans debt prepayment

## Summary
- Q1 revenue $168M, net loss $52M; adjusted EBITDA loss $1.8M vs prior adj EBITDA $26.9M (not comparable due to fresh start accounting).
- End-of-period clinical subscribers 197K (+46% YoY); clinical subscription revenue $39M (+32% YoY).
- Core+ subscribers 537K (+6% YoY); ARPU up 13% YoY due to mix shift to higher-value tiers.
- Reaffirms FY2026 guidance: revenue $620-635M, Adj EBITDA $105-115M.
- Expects to pay $37M cash in Q2 to reduce term loan principal by $42M; voluntary solicitation fully subscribed at 68.5% of par.

## SEC filing metadata
- accession: 0001193125-26-210279
- form_type: 8-K
- ticker: WW
- cik: 0000105319
- company_name: WW INTERNATIONAL, INC.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/105319/000119312526210279/0001193125-26-210279-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/105319/000119312526210279/d116881d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-210279
- JSON: https://secwatch.observer/filing/0001193125-26-210279.json
- Plain text: https://secwatch.observer/filing/0001193125-26-210279.txt

## Source-grounded claims
- claim_id: 4c85b95e1976a498d829fc86cc61b6c200b510a8
  claim: WW INTERNATIONAL, INC. reported first quarter of fiscal 2026 ended March 31, 2026 results: revenue $168 million, net income $52.0 million. Guidance reaffirmed.
  evidence_excerpt: Announces First Quarter 2026 Results Total End of Period Subscribers of 2.7 million; End of Period Clinical Subscribers of 197 thousand, up 46% year-over-year Revenue of $168 million; Clinical Subscription Revenue of $39 million, up 32% year-over-year Reaffirms Full Year 2026 Financial Guidance Announces Fully Subscribed Debt Prepayment Solicitation as Part
  evidence_url: https://www.sec.gov/Archives/edgar/data/105319/000119312526210279/0001193125-26-210279-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.